Dermavant Reports the First Patient Dosing in P-III ADORING Program of Tapinarof for the Treatment of Atopic Dermatitis
Shots:
- The first patient has been dosed in a P-III program that consists of P-III ADORING 1/2 and long-term extension ADORING 3 study evaluates the safety and efficacy of tapinarof (1% dosed- qd) vs vehicle-controlled cream in patients aged ≥2yrs. with AD
- The 1EPs of ADORING 1/2 studies will be the proportion of patients achieving a vIGA-AD of 0 or 1 with at least a 2-grade improvement from baseline @8wks. Additionally- the ADORING 3 study will consist of up to 48wks. with a 7-day safety follow-up period
- Tapinarof is a steroid-free- cosmetically elegant topical cream & a therapeutic aryl hydrocarbon receptor modulating agent for the treatment of PsO and AD
| Ref: Businesswire | Image: PharmaLive
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com